Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355117 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398212 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896049 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486287 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486214 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL119497 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896048 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL6038102 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1564185 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398684 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-108440654-B | Synthesis method of antibacterial active cyclic hexapeptide Thermoactinamide A | 暨南大学 | 2020-09-04 | — | — | CN | claimed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117120458-A | Peptide ligands targeting carbonic anhydrase IX, peptide structures comprising the same, and uses thereof | C-比奥麦克斯有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230174576-A1 | BETA-STRAND BRIDGE PEPTIDE | KYOTO UNIVERSITY (JP) | 2023-06-08 | — | — | US | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| CN-108440654-B | Synthesis method of antibacterial active cyclic hexapeptide Thermoactinamide A | 暨南大学 | 2020-09-04 | — | — | CN | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| CN-102037092-A | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL IND LTD | 2011-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | CASP3 3300/4885MDM4 476/4885TP53 10/4885 |
| US-20230174576-A1 | BETA-STRAND BRIDGE PEPTIDE | IAPP, SPPL2B, VIP | CASP3 2595/4885MDM4 1478/4885TP53 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.